FDA's oncology head Rick Pazdur defends the accelerated approval pathway, claiming it is 'under attack'

Zachary Brennan

Senior Editor

The FDA is sounding the alarm over its accelerated approval pathway as backlash continues over the recent nod in favor of Biogen’s Alzheimer’s drug Aduhelm …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA's oncology head Rick Pazdur defends the accelerated approval pathway, claiming it is 'under attack'

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

New CBER chief Prasad is readying 'massive framework' around vaccines, Makary says

Eli Lilly turns to South Korean RNA editing biotech for hearing loss in deal worth $1.3B

Bristol Myers CEO says America’s biopharma pole position is not guaranteed

Exclusive: Drug compounder Empower was built on risky shortcuts, ex-employees and inspections allege

FDA's on­col­o­gy head Rick Paz­dur de­fends the ac­cel­er­at­ed ap­proval path­way, claim­ing it is 'un­der at­tack'

Senior Editor

Sign up to read this article for free.

more like this

ImmunityBio, Inc.

Remote

FDA's oncology head Rick Pazdur defends the accelerated approval pathway, claiming it is 'under attack'